PDK4 and diffuse large B-cell lymphoma: In our research, we achieved targeted delivery of rituximab and intracellular delivery of siPDK4, enhancing the expression of the membrane protein CD20 by inhibiting the PDK4/HDAC8/CD20 signaling pathway, ultimately eliminating the pathogenicity and resistance of DLBCL cells.